{"id":"iguratimod-tablets","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Infection"}]},"_chembl":{"chemblId":"CHEMBL2107455","moleculeType":"Small molecule","molecularWeight":"374.37"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Iguratimod inhibits the production of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-8, while also promoting the differentiation of regulatory T cells. It acts through multiple pathways including NF-κB signaling inhibition and has been shown to reduce synovial inflammation and joint damage in rheumatoid arthritis models.","oneSentence":"Iguratimod is a small-molecule immunomodulator that suppresses inflammatory cytokine production and modulates immune cell function to reduce inflammation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:48:04.978Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"}]},"trialDetails":[{"nctId":"NCT07115641","phase":"NA","title":"Clinical Trial of Huoluo Pills Combined With Iguratimod Tablets in the Treatment of Rheumatoid Arthritis","status":"NOT_YET_RECRUITING","sponsor":"Wangjing Hospital, China Academy of Chinese Medical Sciences","startDate":"2025-08-11","conditions":"Rheumatoid Arthritis","enrollment":240},{"nctId":"NCT04981145","phase":"PHASE4","title":"The Efficacy and Safety of Iguratimod (IGU) in the Treatment of Primary Sjögren's Syndrome","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-01-14","conditions":"Primary Sjögren's Syndrome","enrollment":78},{"nctId":"NCT06146972","phase":"PHASE4","title":"Efficacy Study of Iguratimod Combined With Tofacitab in Patients With RF Positive/Negative Rheumatoid Arthritis","status":"RECRUITING","sponsor":"Yanfeng Hou","startDate":"2021-06-01","conditions":"Rheumatoid Arthritis, Therapy","enrollment":117},{"nctId":"NCT04928066","phase":"PHASE4","title":"The Efficacy and Safety of Tofacitinib (TF) With Iguratimod (IGU) on RA","status":"COMPLETED","sponsor":"Qilu Hospital of Shandong University","startDate":"2020-03-01","conditions":"Arthritis, Rheumatoid","enrollment":100},{"nctId":"NCT03855007","phase":"PHASE4","title":"The Clinical Efficacy and Safety of Iguratimod in RA and Early RA Patients for 6 Months Treatment","status":"COMPLETED","sponsor":"Qilu Hospital of Shandong University","startDate":"2016-01-01","conditions":"Arthritis, Rheumatoid","enrollment":400},{"nctId":"NCT05626348","phase":"PHASE4","title":"The Clinical Efficacy of Immunomodulators in RA Patients","status":"RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2021-12-22","conditions":"Arthritis, Rheumatoid","enrollment":400},{"nctId":"NCT05216757","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Iguratimod in Patients With Hand Osteoarthritis (ESIGO)","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2022-03","conditions":"Hand Osteoarthritis, Inflammatory Arthritis","enrollment":150},{"nctId":"NCT01554917","phase":"PHASE4","title":"A Study of Iguratimod in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2012-05","conditions":"Rheumatoid Arthritis","enrollment":1759},{"nctId":"NCT01850966","phase":"","title":"Investigation of the Safety and Efficacy of Iguratimod in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2012-09-12","conditions":"Rheumatoid Arthritis","enrollment":2747},{"nctId":"NCT01548001","phase":"PHASE4","title":"Long-term Efficacy of Iguratimod Alone or Iguratimod in Combination With Methotrexate in Patients With Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2012-05","conditions":"Rheumatoid Arthritis","enrollment":910},{"nctId":"NCT02275299","phase":"PHASE4","title":"Study of Iguratimod Plus Methotrexate Compared to Leflunomid Plus Methotrexate in Patients With Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2013-09","conditions":"Rheumatoid Arthritis","enrollment":240},{"nctId":"NCT01893151","phase":"PHASE4","title":"Effectiveness of Iguratimod Versus Placebo to Treat Early Rheumatoid Arthritis on MRI","status":"UNKNOWN","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2012-07","conditions":"Rheumatoid Arthritis","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Iguratimod Tablets","genericName":"Iguratimod Tablets","companyName":"Wangjing Hospital, China Academy of Chinese Medical Sciences","companyId":"wangjing-hospital-china-academy-of-chinese-medical-sciences","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Iguratimod is a small-molecule immunomodulator that suppresses inflammatory cytokine production and modulates immune cell function to reduce inflammation. Used for Rheumatoid arthritis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}